OUTLOOK THERAPEUTICS INC (OTLK)
Outlook Therapeutics, Inc. is a NASDAQ-listed common stock issuer in the healthcare sector focused on biotechnology. The company operates as a clinical-stage biopharmaceutical business developing monoclonal antibody therapies for use in ophthalmic indications. Its lead candidate, ONS-5010, is an ophthalmic bevacizumab formulation being studied in Phase III clinical trials for wet age-related macular degeneration and other retinal diseases. Outlook Therapeutics also has collaboration agreements with Cencora. The company was incorporated in 2010, changed its name from Oncobiologics, Inc. in November 2018, and is based in Iselin, New Jersey.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OTLK
|
$0.50
|
-28.5% Downside
|
Overvalued
|
$5.03
|
622.0% Upside
|
Bargain
|
Fair
|
0.0%
|
December 24, 2026
|
169.5 M
|
174.1 M
|
9.9%
|
80.6%
|
-39.5
|
91.9%
|
